Last10K.com

Bluebird Bio, Inc. (BLUE) SEC Filing 10-K Annual report for the fiscal year ending Tuesday, December 31, 2013

Bluebird Bio, Inc.

CIK: 1293971 Ticker: BLUE

Exhibit 99.1

 

LOGO    NEWS RELEASE

bluebird bio Reports Fiscal Year End 2013 Financial Results

CAMBRIDGE, MA, March 5, 2014 – bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and orphan diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2013. At fiscal year end bluebird bio held $206.3 million in cash and cash equivalents.

Pipeline Update and 2013 Highlights

Lenti-D (Childhood Cerebral Adrenoleukodystrophy)

 

    Starbeam Study: In October 2013, the first patient in the phase 2/3 Starbeam (ALD-102) study was transplanted with bluebird’s Lenti-D product candidate. This study is planned to enroll 15 patients with childhood cerebral adrenoleukodystrophy with at least 12 patients being evaluable. The primary endpoint of the study is the percentage of patients that do not develop a major functional disability at 24 months after their transplant. We anticipate completing enrollment in 2015.

LentiGlobin (beta Thalassemia and Sickle Cell Disease)

 

    HGB-205 Study: In November 2013, the first patient in the phase 1/2 HGB-205 study was transplanted with bluebird’s LentiGlobin product candidate. The HGB-205 study is planned to enroll 7 patients with beta thalassemia major or sickle cell disease at a single site in Paris, France. We anticipate that the first sickle cell patient will be transplanted in this study in 2014.

 

    Northstar Study: The Northstar (HGB-204) study is a US phase 1/2 study that is planned to enroll 15 patients with thalassemia major. The first patient in this study is expected to be transplanted in early 2014.

 

    bluebird bio plans to present preliminary data from the HGB-205 and Northstar studies in late 2014.

 

    Sickle Cell Disease Study: bluebird bio anticipates filing an IND in mid-2014 to start a study with LentiGlobin in patients with sickle cell disease.

Financial Results

Total revenues were $20.2 million during the year ended December 31, 2013 compared to $0.3 million for the year ended December 31, 2012 and include amounts allocated to research and development services from bluebird bio’s collaboration with Celgene Corporation.


The following information was filed by Bluebird Bio, Inc. (BLUE) on Wednesday, March 5, 2014 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Bluebird Bio, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Bluebird Bio, Inc..

Continue

Assess how Bluebird Bio, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Bluebird Bio, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2014 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Document And Entity Information
Consolidated Balance Sheets
Consolidated Balance Sheets (parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit)
Consolidated Statements Of Convertible Preferred Stock And Stockholders' Equity (deficit) (parenthetical)
Consolidated Statements Of Operations And Comprehensive Loss
401(k) Savings Plan
401(k) Savings Plan - Additional Information (detail)
Accrued Expenses And Other Current Liabilities
Accrued Expenses And Other Current Liabilities (tables)
Accrued Expenses And Other Current Liabilities - Summary Of Accrued Expenses And Other Current Liabilities (detail)
Cash And Cash Equivalents
Cash And Cash Equivalents (tables)
Cash, Cash Equivalents, And Marketable Securities - Additional Information (detail)
Cash, Cash Equivalents, And Marketable Securities - Summary Of Cash And Cash Equivalents Carried At Fair Value (detail)
Commitments And Contingencies
Commitments And Contingencies (tables)
Commitments And Contingencies - Additional Information (detail)
Commitments And Contingencies - Future Minimum Commitments Under Facility Operating Leases (detail)
Common Stock And Preferred Stock
Common Stock And Preferred Stock (tables)
Common Stock And Preferred Stock - Additional Information (detail)
Common Stock And Preferred Stock - Summary Of Future Issuance Of Common Stock Shares (detail)
Convertible Preferred Stock
Convertible Preferred Stock - Additional Information (detail)
Description Of The Business
Income Taxes
Income Taxes (tables)
Income Taxes - Additional Information (detail)
Income Taxes - Net Deferred Tax Assets (detail)
Income Taxes - Reconciliation Of Income Tax Expense Computed At The Statutory Federal Income Tax Rate To Income Taxes As Reflected In The Financial Statements (detail)
Income Taxes - Schedule Of Components Of Loss Before Income Taxes (detail)
Net Loss Per Share
Net Loss Per Share (tables)
Net Loss Per Share - Common Stock Equivalents Excluded From Calculation Of Diluted Net (loss) Income Per Share Because Including Them Would Have An Anti-dilutive Effect (detail)
Property And Equipment, Net
Property And Equipment, Net (tables)
Property And Equipment, Net - Additional Information (detail)
Property And Equipment, Net - Property And Equipment (detail)
Restricted Cash
Restricted Cash - Additional Information (detail)
Selected Quarterly Financial Data (unaudited)
Selected Quarterly Financial Data (unaudited) (tables)
Selected Quarterly Financial Data - Quarterly Financial Information (detail)
Significant Agreements
Significant Agreements - Additional Information (detail)
Stock-based Compensation
Stock-based Compensation (tables)
Stock-based Compensation - Additional Information (detail)
Stock-based Compensation - Assumptions Used For The Black-scholes Option-pricing Model To Determine The Per Share Weighted Average Fair Value For Options Granted (detail)
Stock-based Compensation - Summary Of Restricted Common Stock (detail)
Stock-based Compensation - Summary Of Share-based Compensation Expense (detail)
Stock-based Compensation - Summary Of Stock Option Activity Under Plan (detail)
Subsequent Events
Subsequent Events - Additional Information (detail)
Summary Of Significant Accounting Policies And Basis Of Presentation
Summary Of Significant Accounting Policies And Basis Of Presentation (policies)
Summary Of Significant Accounting Policies And Basis Of Presentation (tables)
Summary Of Significant Accounting Policies And Basis Of Presentation - Additional Information (detail)
Summary Of Significant Accounting Policies And Basis Of Presentation - Estimated Useful Lives Of Assets (detail)
Warrants
Warrants (tables)
Warrants - Additional Information (detail)
Warrants - Fair Value Of Warrant To Purchase Shares (detail)
Warrants - Summary Of Changes In Fair Value Preferred Stock Warrant Liability (detail)
Warrants - Warrant Liabilities Measured At Fair Value (detail)
Warrants - Warrants Outstanding (detail)
Ticker: BLUE
CIK: 1293971
Form Type: 10-K Annual Report
Accession Number: 0001193125-14-084683
Submitted to the SEC: Wed Mar 05 2014 4:55:04 PM EST
Accepted by the SEC: Wed Mar 05 2014
Period: Tuesday, December 31, 2013
Industry: Biological Products No Disgnostic Substances

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/blue/0001193125-14-084683.htm